In the whole course of DAA treatment or during the 12-week follow-up period, glucose control in T2DM patients by oral medicine does not reduce the dosage of drugs, but there was a decrease in insulin use among those who underwent treatment by insulin [32]. The gene discussed is INS; the disease is type 2 diabetes mellitus.